Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:603882's Days Payable is ranked better than 74.74% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.64
vs SHSE:603882: 150.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Kingmed Diagnostics Group Co Days Payable Chart
Guangzhou Kingmed Diagnostics Group Co Annual Data
SHSE:603882 vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Guangzhou Kingmed Diagnostics Group Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Kingmed Diagnostics Group Co Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guangzhou Kingmed Diagnostics Group Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Guangzhou Kingmed Diagnostics Group Co's Days Payable falls into.
Guangzhou Kingmed Diagnostics Group Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) has a Days Payable of 153.75 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Guangzhou Kingmed Diagnostics Group Co and its competitors. This is 36% above median its historical median of 113.08. Over the past decade, Guangzhou Kingmed Diagnostics Group Co's Days Payable has ranged from 101.11 to 170.01. According to the industry distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #48 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 25.3%.
Is Guangzhou Kingmed Diagnostics Group Co's Days Payable too high?
Guangzhou Kingmed Diagnostics Group Co's current Days Payable of 153.75 is 36% above median its 10-year median of 113.08. Over the past 10 years, this metric has ranged from a low of 101.11 to a high of 170.01. The Medical Diagnostics & Research industry median Days Payable is 64.64. Guangzhou Kingmed Diagnostics Group Co's value of 153.75 is 137.9% above this industry median. Based on the distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #48 out of 190 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Guangzhou Kingmed Diagnostics Group Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Kingmed Diagnostics Group Co's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #48 out of 190 companies for Days Payable. This puts Guangzhou Kingmed Diagnostics Group Co in the upper half of its industry. The industry median Days Payable is 64.64. Guangzhou Kingmed Diagnostics Group Co's value of 153.75 is 137.9% above this benchmark. Historically, Guangzhou Kingmed Diagnostics Group Co's own Days Payable has ranged from 101.11 to 170.01 over the past decade. While the company's 10-year median is 113.08 vs. the industry median of 64.64, Guangzhou Kingmed Diagnostics Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.64, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guangzhou Kingmed Diagnostics Group Co's current Days Payable of 153.75 is 137.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Guangzhou Kingmed Diagnostics Group Co and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangzhou Kingmed Diagnostics Group Co's current Days Payable is 153.75, which is 36% above median its own 10-year median of 113.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Kingmed Diagnostics Group Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) is currently considered Fairly Valued. The stock's GF Value™ is ¥27.91, compared to a current price of ¥26.71 — trading 4.3% below its estimated fair value. The current Days Payable is 153.75, which is 36% above median its 10-year median of 113.08 and 137.9% above the Medical Diagnostics & Research industry median of 64.64. Guangzhou Kingmed Diagnostics Group Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Guangzhou Kingmed Diagnostics Group Co (SHSE:603882), the current Days Payable is 153.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Kingmed Diagnostics Group Co stock appears to be undervalued.
The current stock price of ¥26.71 is trading 4.3% below its estimated GF Value™ of ¥27.91.
GuruFocus considers Guangzhou Kingmed Diagnostics Group Co to be Fairly Valued.
Key valuation signals for SHSE:603882:
Days Payable: 153.75 (36% above median its 10-year median of 113.08)
GF Value™: ¥27.91 vs. price of ¥26.71 (4.3% below fair value)
Industry Position: 137.9% above the Medical Diagnostics & Research median (#48 of 190)
No single metric tells the full story. See the SHSE:603882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangzhou Kingmed Diagnostics Group Co Business Description
Founded in 1994, KingMed is the largest independent clinical laboratory in China. It was listed on the Shanghai Stock Exchange in 2017. As of 2024, KingMed has 50 centralized labs and provides over 4000 test items. Over 90% of its total revenue comes from clinical diagnostics. Furthermore, KingMed has been actively investing in its cold chain logistics. Its service network covers the most intensely populated areas in China.
74GF Score
Get the complete analysis for SHSE:603882
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603882 has been successfully added to your 
